This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sordet, O. Articles by Pommier, Y. Search for Related Content PubMed PubMed Citation Articles by Sordet, O. Articles by Pommier, Y.

Research Articles: Therapeutics, Targets, and Development

Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes

Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland

Requests for reprints: Yves Pommier, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Building 37, Room 5068, Bethesda, MD 20892-4255. Phone: 301-496-5944; Fax: 301-402-0752. E-mail: pommier{at}nih.gov

Abstract

Topoisomerase I (Top1) is a ubiquitous enzyme that removes DNA supercoiling generated during transcription and replication. Top1 can be trapped on DNA as cleavage complexes by the anticancer drugs referred to as Top1 inhibitors as well as by alterations of the DNA structure. We reported recently that Top1 cleavage complexes (Top1cc) are trapped during apoptosis induced by arsenic trioxide and staurosporine. In the present study, we generalize the occurrence of apoptotic Top1cc in response to anticancer drugs, which by themselves do not directly interact with Top1: the topoisomerase II inhibitors etoposide, doxorubicin, and amsacrine, and the tubulin inhibitors vinblastine and Taxol. In all cases, the Top1cc form in the early phase of apoptosis and persist throughout the apoptotic process. Their formation is prevented by the caspase inhibitor benzyloxycarbonyl-Val-Ala-DL-Asp(OMe)-fluoromethylketone and the antioxidant N-acetyl-L-cysteine. We propose that the trapping of Top1cc is a general process of programmed cell death, which is caused by alterations of the DNA structure (oxidized bases and strand breaks) induced by caspases and reactive oxygen species. [Mol Cancer Ther 2006;5(12):3139–44]

Grant support: Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ O. Sordet et al., submitted for publication.

Received 8/ 4/06; revised 10/ 5/06; accepted 10/27/06.

This article has been cited by other articles:

				O. Sordet, A. Goldman, C. Redon, S. Solier, V. A. Rao, and Y. Pommier Topoisomerase I Requirement for Death Receptor-induced Apoptotic Nuclear Fission J. Biol. Chem., August 22, 2008; 283(34): 23200 - 23208. [Abstract] [Full Text] [PDF]

				A. Ganguly, B. Das, A. Roy, N. Sen, S. B. Dasgupta, S. Mukhopadhayay, and H. K. Majumder Betulinic Acid, a Catalytic Inhibitor of Topoisomerase I, Inhibits Reactive Oxygen Species Mediated Apoptotic Topoisomerase I DNA Cleavable Complex Formation in Prostate Cancer Cells but Does Not Affect the Process of Cell Death Cancer Res., December 15, 2007; 67(24): 11848 - 11858. [Abstract] [Full Text] [PDF]